Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | TRK-950 |
Trade Name | |
Synonyms | TRK 950|TRK950 |
Drug Descriptions |
TRK-950 is a monoclonal antibody that targets Caprin-1, potentially leading to antitumor activity (European Journal of Cancer 174 (2022): S32-S33). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | C142826 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Carboplatin + Gemcitabine + TRK-950 | Carboplatin Gemcitabine TRK-950 | 0 | 1 |
Cisplatin + Gemcitabine + TRK-950 | Cisplatin Gemcitabine TRK-950 | 0 | 1 |
Fluorouracil + Irinotecan + Leucovorin + TRK-950 | Fluorouracil Irinotecan Leucovorin TRK-950 | 0 | 1 |
Gemcitabine + TRK-950 | Gemcitabine TRK-950 | 0 | 0 |
Imiquimod + TRK-950 | Imiquimod TRK-950 | 0 | 1 |
Nivolumab + TRK-950 | Nivolumab TRK-950 | 0 | 1 |
Paclitaxel + Ramucirumab + TRK-950 | Paclitaxel Ramucirumab TRK-950 | 0 | 2 |
Pembrolizumab + TRK-950 | Pembrolizumab TRK-950 | 0 | 1 |
TRK-950 | TRK-950 | 0 | 1 |